dicitabine + triplezumab

This is a combination drug consisting of dicitabine (likely a misspelling or variant spelling of decitabine, a well-established hypomethylating agent) and triplezumab (no evidence found for an approved or investigational monoclonal antibody named "triplezumab"). Decitabine is a small molecule antimetabolite that inhibits DNA methyltransferase, leading to DNA hypomethylation and altered gene expression, primarily used in the treatment of myelodysplastic syndromes and acute myeloid leukemia[6][8][10]. Triplezumab does not correspond to any known monoclonal antibody in clinical use or development as of June 2025. Therefore, this combination appears to be either hypothetical, incorrectly named, or not present in the current scientific literature.